Paper Details

  1. Home
  2. Paper Details

Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.

Author: BrarJaspreet S, ChengappaK N Roy, GeorgeTony P, HetrickMichelle L, LevineMichele D, PerkinsKenneth A, SchlichtPatricia J, TurkinScott R

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Varenicline, a medication for smoking cessation, was assessed in euthymic bipolar subjects motivated to quit smoking.
Paper Details　
Original Abstract of the Article :
Virtually no clinical trials for smoking cessation have been undertaken in bipolar disorder. Varenicline has shown efficacy for smoking cessation, but warnings about neuropsychiatric adverse events have been issued. We assessed the efficacy and safety of varenicline in euthymic bipolar subjects moti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4088/JCP.13m08756

データ提供：米国国立医学図書館（NLM）

The Quest for Smoke-Free Horizons in Bipolar Disorder

Quitting smoking is a journey fraught with challenges, but for those with bipolar disorder, it’s like traversing a desert with unpredictable sandstorms. This study is like an expedition, exploring the effectiveness and safety of varenicline, a medication used for smoking cessation, in individuals with bipolar disorder.

Finding a Path to Quitting

The researchers, like seasoned adventurers, sought to find a safe and effective route to quitting smoking for individuals with bipolar disorder. They conducted a randomized, double-blind, placebo-controlled study to evaluate the efficacy of varenicline. The results of this study are crucial for understanding the potential benefits and risks of varenicline in this population.

A Hopeful Beacon for Smokers with Bipolar Disorder

This research offers a beacon of hope for those with bipolar disorder who struggle with smoking. It provides valuable information about the potential benefits and risks of varenicline, helping individuals make informed decisions about their treatment options. It’s like finding a wellspring of knowledge in the desert, providing a lifeline for those seeking to quit.

Dr.Camel's Conclusion

This study offers a beacon of hope for those with bipolar disorder who struggle with smoking, providing valuable information about the potential benefits and risks of varenicline, helping individuals make informed decisions about their treatment options. It’s like finding a wellspring of knowledge in the desert, providing a lifeline for those seeking to quit.

Date :
  1. Date Completed 2014-10-01
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

25006684

DOI: Digital Object Identifier

10.4088/JCP.13m08756

Related Literature

Article Analysis
・Side Effects of varenicline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.